Evidence map›Paper›PMID 39236296›Full record

ArticleMicrobial biotechnology2024

Concepts and criteria defining emerging microbiome applications.

Tanja Kostic, Michael Schloter, Paulo Arruda, Gabriele Berg, Trevor C Charles, Paul D Cotter, George Seghal Kiran, Lene Lange, Emmanuelle Maguin, Annelein Meisner and 8 more

Abstract read
In one paragraph

Article in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Microbes Saving Lives and Reducing Suffering.Microbial biotechnology · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tanja KosticAIT Austrian Institute of Technology GmbH, Vienna, Austria.ORCID 0000-0003-4972-4141
Michael SchloterHelmholtz Zentrum München, Oberschleissheim, Germany.
Paulo ArrudaState University of Campinas, Campinas, Brazil.
Gabriele BergGraz University of Technology, Graz, Austria.
Trevor C CharlesUniversity of Waterloo, Waterloo, Ontario, Canada.
Paul D CotterTeagasc Food Research Centre, Moorepark, APC Microbiome Ireland and VistaMilk, Cork, Ireland.
George Seghal KiranPondicherry University, Puducherry, India.
Lene LangeLL-BioEconomy, Research and Advisory, Copenhagen, Denmark.
Emmanuelle MaguinUniversité Paris-Saclay, INRAE, AgroParisTech, MICALIS UMR1319, Jouy-en-Josas, France.
Annelein MeisnerWageningen University & Research, Wageningen Research, Wageningen, The Netherlands.
Leo van OverbeekWageningen University & Research, Wageningen Research, Wageningen, The Netherlands.
Yolanda SanzInstitute of Agrochemistry and Food Technology - Spanish National Research Council (IATA-CSIC), Paterna, Valencia, Spain.
Inga SarandTallinn University of Technology, Tallinn, Estonia.
Joseph SelvinPondicherry University, Puducherry, India.
Effie TsakalidouAgricultural University of Athens, Athens, Greece.
Hauke SmidtLaboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands.
Martin WagnerFFoQSI GmbH - Austrian Competence Centre for Feed and Food Quality, Safety and Innovation, Tulln, Austria.
Angela SessitschAIT Austrian Institute of Technology GmbH, Vienna, Austria.ORCID 0000-0003-0137-930X

Funding

Horizon 2020 Framework Programme 818116
6 · The paper itself

Abstract

In recent years, microbiomes and their potential applications for human, animal or plant health, food production and environmental management came into the spotlight of major national and international policies and strategies. This has been accompanied by substantial R&D investments in both public and private sectors, with an increasing number of products entering the market. Despite widespread agreement on the potential of microbiomes and their uses across disciplines, stakeholders and countries, there is no consensus on what defines a microbiome application. This often results in non-comprehensive communication or insufficient documentation making commercialisation and acceptance of the novel products challenging. To showcase the complexity of this issue we discuss two selected, well-established applications and propose criteria defining a microbiome application and their conditions of use for clear communication, facilitating suitable regulatory frameworks and building trust among stakeholders.

Indexed as

MicrobiotaAnimalsHumans

Identifiers

PMID39236296
PMCPMC11376781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.